贝那普利联合坎地沙坦逆转高血压患者左心室肥厚疗效分析被引量：8

下载PDF

导出

摘要目的探讨ACEI和ARB联合治疗对原发性高血压(EH)患者左心室肥厚(LVH)的逆转。方法将169例伴LVH的EH患者随机分成贝那普利组、坎地沙坦组和联合治疗组。设定血压达标值为收缩压(SBP)<140mmHg(1mmHg=0.133kPa)和舒张压(DBP)<90mmHg。3组患者分别口服起始剂量贝那普利10mg/d、坎地沙坦4mg/d和贝那普利10mg/d加坎地沙坦4mg/d。随访周期为2周,若血压未能达标,则增加剂量直至联合治疗,最大剂量为贝那普利20mg/d加坎地沙坦8mg/d。3组患者均口服氢氯噻嗪12.5mg/d。总疗程20周。检测治疗前后24h动态血压、左室质量指数(LVMI)和心率(HR)。结果①3组治疗后24hmSBP、24hmDBP均分别较治疗前显著降低(均P<0.01),而3组治疗前后24hmSBP、DBP的降低幅度差异均无统计学意义(均P>0.05)。②3组治疗后LVMI和HR均分别较治疗前显著性降低(均P<0.01)。联合治疗组治疗前后LVMI和HR的降低幅度均分别大于贝那普利组和坎地沙坦组,差异均具有统计学意义(均P<0.05)。结论贝那普利联合坎地沙坦联合治疗在逆转LVH和抑制心脏交感活性方面较贝那普利或坎地沙坦单药治疗具有更加显著的作用,且这些作用独立于降压疗效之外。

作者张海波李宝枢

机构地区吉林省四平市第四人民医院心内科

出处《中国实用医药》 2013年第1期149-151,共3页 China Practical Medicine

关键词高血压左室肥厚贝那普利坎地沙坦联合治疗

分类号 R544.1 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献5

1FRANZ H M,REINHARD K. Left ventricular hypertroply:a pressure independent cardiovascular riskhrtor[J].Journal of Cardiovascular Pharmacology and therapeutics,1993,(Suppl 1):S7-S13.
2DEVEREUX RB. Detection of lele ventricular hypertrophy by M-mode echocardiography,validation,standardization,and comparison to other methods[J].Hypertension,1987.S19-S26.
3LoRELL B H. Cardiac renin-angiotensin system:Role in development of pressure-overload hypertrophy[J].Canadian Journal of Cardiology,1995,(Suppl F):7F-12F.
4张苏川,仇克难,何彭孙,汪湛,徐福禄,刘敏,徐亚宁.苯那普利及缬沙坦联合治疗对原发性高血压左室肥厚的逆转作用[J].临床心血管病杂志,2003,19(7):396-398. 被引量：18
5李春兰,董钰明,张振义.贝那普利联合氯沙坦对老年高血压脉压、心功能及左室肥厚的影响[J].兰州大学学报（医学版）,2005,31(4):25-29. 被引量：10

二级参考文献19

1王凡,刘国树.大动脉顺应性减退的机制研究[J].国外医学（心血管疾病分册）,2005,32(5):275-278. 被引量：15
2[1]Stanley S,Franklin M D,Shehzad D,et al.Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study[J].Circulation,1999,100(4):354-360.
3[2]Mansoor G A,Massie B M.Left ventricular hypertrophy:a potent cardiovascular risk factor and its relationship to office and ambulatory blood pressure[J].Blood Pressure Monit,1999,4(Suppl 1):19-22.
4[3]Devereux R B,Alonso D R,Lutas E M,et al.Echocardiography assessment of left ventricular hypertrophy:comparison to necropsy findings[J].Am J Cardiol,1986,57(6):450-458.
5[4]Zakopoulos N A,Lekakis J P,Papamichael C M,et al.Pulse pressure in normotensive:a marker of cardiovascular disease[J].Am J Hypertension,2001,14(3):195-199.
6[6]Mitchell G F,Moye L A,Braunwald E,et al.Sphygmomanometer determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function[J].Circulation,1997,96(12):4254-4260.
7[7]Benetos A,Rudnichi A,Safar M,et al.Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects[J].Hypertension,1998,32(3):560-564.
8[9]Weber K T,Anversa P,Armstrong P W,et al.Remodeling and reparation of the cardiovascular system[J].J Am Coll Cardiol,1992,20(1):3-16.
9[10]Sharifi A M,Schiffrin E L.Apoptosis in vasculature of spontaneously hypertensive rats:effect of an angiotensin converting inhibitor and a calcium channel antagonist[J].Am J Hypertension,1998,11(9):1108-1116.
10[11]Deblois D,Tea B S,Than V D,et al.Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats[J].Hypertension,1997,29(1):340-349.